Maria Teresa Lupo Stanghellini, MD San Raffaele Scientific Institute. Milano, Italy.

Size: px
Start display at page:

Download "Maria Teresa Lupo Stanghellini, MD San Raffaele Scientific Institute. Milano, Italy. m.lupostanghellini@hsr.it"

Transcription

1 : in-vivo HSV-TK suicide machinery is effective in GvHD control and provide a long-term immune-suppressive treatment-free survival Maria Teresa Lupo Stanghellini, MD San Raffaele Scientific Institute. Milano, Italy

2 Haplo-HSCT: a difficult GvHD setting The holy grail of haplo-hsct is to mitigate host-versusgraft and graft-versus-host response while preserving immune responses to infection and the patient s malignancy. Fuchs Hematology 2012

3 Chronic GvHD is NOT beneficial The presence of chronic GVHD is associated with significantly higher treatment-related mortality and worse overall survival across all diseases studied Boyiadzidis et al 2014

4 Haplo-HSCT and T-cell depletion Trends in alternative donor transplantation. EBMT 2013 activity survey Haplo-SCT without T-cell depletion (TCD) is increasingly used, but follow-up is still short to evaluate the impact of chronic GvHD in such a mismatched setting

5 HSV-TK approach: a 20 years history TK cells therapy in haploidentical-hsct Donor haematopoietic stem cells Hospital TK cells Protection from infections Haemat. stem cells Day 0 Day 21+ TK cells Protection from leukaemia relapse Haploidentical donor MolMed GMP facility Genetic engineering of donor T cells No immunesuppression needed (prompt abrogation of GvHD by administration of ganciclovir) T cells Donor T cells HSV-TK Sources: adapted from Bonini et al., Science 1997; Bonini et al., Nat. Med. 2003; Recchia et al., PNAS 2006; Ciceri et al, Blood 2007; Ciceri, Bonini et al., The Lancet Oncology 2009; Oliveira, Curr Opin Hematol 2012 MolMed S.p.A. TK008_IPR/21_Start-up - CONFIDENTIAL 5

6 TK-cells and GvHD kinetics: series analysis 57 adult patients (pts) after haplo-sct for hematologic malignancies years Phase II TK007 trial (Ciceri, Bonini et al, Lancet Oncol 2009) Phase III TK008 trial (NCT ) Graft: peripheral CD34+ selected cells No post-transplant immune-suppression after transplantation as GvHD prophylaxis

7 Study design Phase I-II TK007 NCT Ciceri, Bonini et al, Lancet Oncol 2009 Phase III TK008 NCT Haplo-HSCT* plus TK cells Haplo-HSCT* plus TK cells R (3:1) Haplo-HSCT** *T-depleted (T cells, 1x10 4 /Kg) *T-depleted (T cells, 1x10 4 /Kg) **T-depleted (T cells, 1x10 4 /Kg) or ** unmanipulated BMT/PB + HD CTX Dose of TK cells (1-x10 7 /Kg - 1x10 7 /Kg) Up to 4 monthly doses up to IR (CD3+ cell count >/= 100/mcl) Starting 21 to 49 days after HSCT in absence of IR and/or GvHD Dose of TK cells (1x10 7 /Kg) Up to 4 monthly doses up to IR (CD3+ cell count >/= 100/mcl) Starting 21 to 49 days after HSCT in absence of IR and/or GvHD

8 Patient population n 57 Median age 53y (range 17-66) Male 26 Diagnosis Acute Leukemia Myelodysplasia Chronic Myeloid Leukemia Hodgkin Disease Non Hodgkin Lymphoma 50 (AML 43) Disease status at transplant Source of Stem Cell HLA match type Female Donor in Male Host 12 Graft Manipulation Median Follow-Up Complete Remission 40 (25 CR1) Persistence of Disease 17 Peripheral Blood HLA-mismatched relative with >/= 2 HLA Ag mismatch peripheral CD34+ cells in vivo T and B cell depletion ATG and Rituximab 79 months (range months)

9 Conditioning Regimen Treosulfan 14 g/m 2 X X X Fludarabine 30 mg/m 2 X X X X X ATG Fresenius 10 mg/kg X X X Rituximab 500 mg X T-cell depleted Haplo-PBSC X TBI 200 cgy X X Donor Lymphocytes Infusion X* *TK-cell based strategy

10 TK-cells therapy Patients treated 35/57 N^ Infusion (median) 2 (1-4) CD3 / Kg x10 7 1,1x10 7 /Kg CD3 dose (total cells x10^6) 931x10 6 Immune-reconstitution: patients median time from SCT median time from last TK-cells infusion 25/35 pts 84 days (18-182) 27 days (13-42) n 35

11 TK008 experimental arm: fast and wide immune reconstitution (IR) cells / ul NGFR+ NGFR- Percentage of CD4 + cells Gated on CD4+ Percentage of CD8 + cells 120 T NA 100 T CM T EM 80 T EM RA Gated on CD8+ T NA T CM T EM T EM RA 0 Baseline n=6 at Immune Reconstitution n=6 at 6 months n=6 at 1 year n=4 0 IR 6m 1y time after HSCT (days) 0 IR 6m 1y time after HSCT (days) Spectratyping Complexity Score IR 6m 1Y CTRL Percentage of CD4 + cells Gated on CD4+LNGFR IR 6m 1y time after HSCT (days) Percentage of CD8 + cells Gated on CD8+LNGFR+ 120 T NA T100 CM T EM 80 T EM RA IR 6m 1y time after HSCT (days) T NA T CM T EM T EM RA MolMed S.p.A. Takara Bio MolMed meeting, 19 July 2013 CONFIDENTIAL 11

12 TK-cells: GvHD n 25 GvHD 13/25 Acute GvHD N^ of patients Onset median time days post SCT (20-162) 42 days post 1 st TK-cell infusion (3-118) Grade I Grade II Grade III Grade IV Chronic GvHD N^ of patients Onset time Feature 2 pts 8 pts 1 pts 1 pts days post SCT 146 days post 1 st TK-cell infusion severe, classic, de novo c-gvhd, with sclerodermatous lichenoid skin and mouth features plus moderate dry-eye symptoms

13 TK-cells and GvHD TK-cells infiltrate GvHD affected organs

14 GvHD : ganciclovir treatment TK+ cells/mcl TK- cells/mcl 400 * 600 p p ns pre post 0 pre post 11/13 pts GvHD treatment with ganciclovir iv or VGC per os full control of clinical manifestations of GvHD in a median of 14 d significant reduction in numbers of circulating TK-cells no reduction of CD3+ TK-negative lymphocytes long-term IR In 5 pts additional concomitant treatment with low-dose steroid (prednisone <0.5mg/kg per day for a median of 2 weeks)

15 GvHD: kinetics of ganciclovir treatment Time to GvHD resolution (n=13). Percent of patients GvHD free median 14 days No cases of quiescent or progressive c-gvhd was observed after a median follow-up of 679 days (r 139/4035).

16 TK-cells: Long-Term-Follow-Up According to international guideline for long-term follow-up all pts underwent regular screening and clinical evaluation. Majhail NS et al, BBMT. 2012; 18: No major infections occurred in the late phase No grade IV adverse events regarding ocular, oral, respiratory, hepatic, renal, genitourinary, muscle-skeletal or neurological systems. Noteworthy 1 pt developed 2 nd cancer (non-melanoma skin cancer ), 3 pts hypothyroidism, 5 pts metabolic syndrome. No evidence of psychosocial symptoms was reported.

17 12-years of TK-cells in Haplo-HSCT: conclusion TK-cells are effective in providing IR while controlling GvHD TK-cells provide a long-term immunosuppressive therapy free survival in absence of GvHD GCV/VGCV treatment of GVHD do not impair a long-term IR Phase III TK008: 1-y DFS and OS (all pts) In vivo persistence of gene modified TK cells Bonini et al, ASH 2014 ABS 2535 Oliveira et al, ASH 2014 ABS 4793

18 Acknowledgement Bone Marrow Transplantation Unit Fabio Ciceri Massimo Bernardi Consuelo Corti Jacopo Peccatori Andrea Assanelli Magda Marcatti Sarah Marktel Francesca Lunghi Elena Guggiari Matteo Carrabba Luca Vago Raffaella Greco HLA Tissue Typing Immunohematology and Transfusion Medicine Laura Bellio Milena Coppola Katharina Fleischhauer Salvatore Gattillo Lucia Malabarba Simona Malato Benedetta Mazzi Paola Ronchi Michela Tassara Elisabetta Zino MolMed Claudio Bordignon Antonio Lambiase Monica Salomoni Scialini Colombi Division of Regenerative Medicine, Stem Cell and Gene Therapy - Experimental Hematology Unit Chiara Bonini Giacomo Oliveira Attilio Bondanza Sara Mastaglio Nicoletta Cieri Zulma Magnani Veronica Valtolina Rosaria Carbone

STUDY PROTOCOL. Fabio Ciceri M.D. Istituto Scientifico H. San Raffaele Dept. of of Oncology, Haematology/Transplant Unit I-20132 Milan

STUDY PROTOCOL. Fabio Ciceri M.D. Istituto Scientifico H. San Raffaele Dept. of of Oncology, Haematology/Transplant Unit I-20132 Milan STUDY PROTOCOL Clinical phase II trial to evaluate the safety and efficacy of treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly

More information

Bone Marrow Transplantation for Severe Aplastic Anemia

Bone Marrow Transplantation for Severe Aplastic Anemia Bone Marrow Transplantation for Severe Aplastic Anemia David A. Margolis, MD Children s Hospital of Wisconsin Medical College of Wisconsin Conference Objectives (cut and pasted from AAMDS.ORG) Learn how

More information

Different Conditioning Regimens. Stephen Mackinnon University College London

Different Conditioning Regimens. Stephen Mackinnon University College London Different Conditioning Regimens Stephen Mackinnon University College London Principles of Dose Intensity Standard chemo dosing limited by marrow toxicity Stem cell rescue allows higher doses of chemo or

More information

Relapse is the leading cause of treatment failure post-hsct. Can we prevent or treat disease relapse?

Relapse is the leading cause of treatment failure post-hsct. Can we prevent or treat disease relapse? Relapse is the leading cause of treatment failure post-hsct Can we prevent or treat disease relapse? Options at relapse - Second transplant - DLI (un manipulated or manipulated) - Leukaemia-specific T

More information

EBMT2008_22_44:EBMT :33 Pagina 506 CHAPTER 36. HSCT for acute lymphoblastic leukaemia in children. T. Klingebiel, P.

EBMT2008_22_44:EBMT :33 Pagina 506 CHAPTER 36. HSCT for acute lymphoblastic leukaemia in children. T. Klingebiel, P. EBMT2008_22_44:EBMT2008 6-11-2008 9:33 Pagina 506 * CHAPTER 36 HSCT for acute lymphoblastic leukaemia in children T. Klingebiel, P. Bader EBMT2008_22_44:EBMT2008 6-11-2008 9:33 Pagina 507 CHAPTER 36 ALL

More information

The EBMT Cellular Therapy and Immunobiology Symposium

The EBMT Cellular Therapy and Immunobiology Symposium The EBMT Cellular Therapy and Immunobiology Symposium From Transplantation to Gene Therapy: Cellular therapy in evolution November 11 th -13 th, 2015 San Raffaele Scientific Institute Chairman Dr. Chiara

More information

Selection of the Optimal Umbilical Cord Blood Unit

Selection of the Optimal Umbilical Cord Blood Unit Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies

More information

Stem Cell Transplantation In Patients with Fanconi Anemia

Stem Cell Transplantation In Patients with Fanconi Anemia Stem Cell Transplantation In Patients with Fanconi Anemia FARF Annual Family Meeting 6/28/15 Casco, ME Parinda A. Mehta, M.D. Cincinnati Children s Hospital Medical Center Improvements in Unrelated Donor

More information

Clinical Commissioning Policy: Second allogeneic haematopoietic stem cell transplant for relapsed disease. Reference: NHS England: 16068/P

Clinical Commissioning Policy: Second allogeneic haematopoietic stem cell transplant for relapsed disease. Reference: NHS England: 16068/P Clinical Commissioning Policy: Second allogeneic haematopoietic stem cell transplant for relapsed disease Reference: NHS England: 16068/P NHS England INFORMATION READER BOX Directorate Medical Operations

More information

FREQUENTLY ASKED QUESTIONS (FAQs) FOR BMT CTN PROTOCOL #0303

FREQUENTLY ASKED QUESTIONS (FAQs) FOR BMT CTN PROTOCOL #0303 FREQUENTLY ASKED QUESTIONS (FAQs) FOR BMT CTN PROTOCOL #0303 1. Why conduct a transplant trial evaluating T cell depletion in acute myeloid leukemia (AML)? Patients with acute myeloid leukemia under the

More information

thiotepa 15mg and 100mg powder for concentrate for solution for infusion (Tepadina ) SMC No. (790/12) Adienne S.r.l.

thiotepa 15mg and 100mg powder for concentrate for solution for infusion (Tepadina ) SMC No. (790/12) Adienne S.r.l. thiotepa 15mg and 100mg powder for concentrate for solution for infusion (Tepadina ) SMC No. (790/12) Adienne S.r.l. 08 June 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of

More information

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells

More information

Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose

Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of

More information

Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP)

Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP) Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP) October 18, 2014 19th Congress of APBMT, Hangzhou, China AMIR ALI HAMIDIEH, MD Iranian

More information

CHAPTER 17. Indications and current practice for allogeneic and autologous HSCT for haematological diseases, solid tumours and immune disorders

CHAPTER 17. Indications and current practice for allogeneic and autologous HSCT for haematological diseases, solid tumours and immune disorders EBMT2008_1_21:EBMT2008 6-11-2008 9:20 Pagina 318 * CHAPTER 17 Indications and current practice for allogeneic and autologous HSCT for haematological diseases, solid tumours and immune disorders P. Ljungman,

More information

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,

More information

Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris

Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is

More information

Comparison of Hematopoietic cell Transplantation with CD34-selected T cell depletion to Unmanipulated Grafts for AML. Marcelo C.

Comparison of Hematopoietic cell Transplantation with CD34-selected T cell depletion to Unmanipulated Grafts for AML. Marcelo C. Comparison of Hematopoietic cell Transplantation with CD34-selected T cell depletion to Unmanipulated Grafts for AML Marcelo C. Pasquini, MD, MS Rationale Single center studies show reduced GVHD without

More information

CliniMACS CD34 Reagent System Ex vivo T cell depletion for GVHD prophylaxis

CliniMACS CD34 Reagent System Ex vivo T cell depletion for GVHD prophylaxis CliniMACS CD34 Reagent System Ex vivo T cell depletion for GVHD prophylaxis For US healthcare professionals only Allogeneic stem cell transplantation in AML Nearly 13,000 people in the United States are

More information

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem

More information

Cell therapy besides HCT Mesenchymal stem cells

Cell therapy besides HCT Mesenchymal stem cells Cell therapy besides HCT Mesenchymal stem cells Katarina Le Blanc Division of Clinical Immunology and Transfusion Medicine, Hematology Center, Karolinska Institutet and Karolinska University Hospital Huddinge,

More information

Hematopoietic Cell Transplantation for Myelofibrosis. H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA

Hematopoietic Cell Transplantation for Myelofibrosis. H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Scottsdale, February 2013 The following diagnoses will

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll

More information

Acute GVHD: Grading and Endpoints

Acute GVHD: Grading and Endpoints Acute GVHD: Grading and Endpoints Paul Martin, MD Fred Hutchinson Cancer Research Center, Seattle, WA Disclosures Contract support for clinical trials Osiris: Mesenchymal stem cells for secondary treatment

More information

MolMed S.p.A. Investor presentation

MolMed S.p.A. Investor presentation an integrated strategy to cure cancer MolMed S.p.A. Investor presentation BIO CEO & Investor Conference, New York (USA) 9 February 2010 Claudio Bordignon Chairman & CEO Forward-looking statements This

More information

Challenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute

Challenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute Challenges of Hematopoietic Stem Cell Transplantation Robert J. Soiffer, MD Dana Farber Cancer Institute Hematopoietic Stem Cell Transplantation Objectives Deliver sufficient chemo-radio therapy to destroy

More information

The EBMT Cellular Therapy and Immunobiology Workin Party Symposium

The EBMT Cellular Therapy and Immunobiology Workin Party Symposium The EBMT Cellular Therapy and Immunobiology Workin Party Symposium From Transplantation to Gene Therapy: Cellular therapy in evolution November 11 th -13 th, 2015 San Raffaele Scientific Institute Chairman

More information

Myeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants

Myeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants Educational 2 Cord Blood Transplantation Myeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants William Arcese University of Rome Tor Vergata Rome Transplant Network 4th April

More information

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy

More information

Joint educational meeting of the EBMT Aplastic Anemia and Complications and QOL Working Parties 1-3 November 2012, Budapest, Hungary

Joint educational meeting of the EBMT Aplastic Anemia and Complications and QOL Working Parties 1-3 November 2012, Budapest, Hungary Joint educational meeting of the EBMT Aplastic Anemia and Complications and QOL Working Parties 1-3 November 2012, Budapest, Hungary Gérard SOCIE, MD, PhD Late Malignancies Acknowledgement: Smita Bhatia;

More information

Organ dysfunction after HSCT Heart

Organ dysfunction after HSCT Heart Organ dysfunction after HSCT Heart Annual Meeting of the EBMT, Paris 2011 EBMT Slide template Barcelona 7 February 2008 Educational 6 Tuesday, 5th April 2011 André Tichelli Chairman Late Effects Working

More information

Allogeneic Hematopoetic Stem cell transplant. A key role to play in management of high risk CLL

Allogeneic Hematopoetic Stem cell transplant. A key role to play in management of high risk CLL Allogeneic Hematopoetic Stem cell transplant A key role to play in management of high risk CLL Why does allogeneic HSCT have an important place in CLL therapy? Strong graft vs leukemia effect Immune anti-cll

More information

Pro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany

Pro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured

More information

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Hagop M. Kantarjian, MD Chairman, Leukemia Department Department of Hematology

More information

Stem Cell Transplantation in Leukemia. D. Niederwieser University of Leipzig Germany

Stem Cell Transplantation in Leukemia. D. Niederwieser University of Leipzig Germany Stem Cell Transplantation in Leukemia D. Niederwieser University of Leipzig Germany probability Stem Cell Transplantation in Acute Myeloid Leukemia Outcome according to cytogenetics AML 96 n = 35, 163,

More information

Navelstrengbloed tegen kanker

Navelstrengbloed tegen kanker Navelstrengbloed tegen kanker THERAPIEDAG 2008: "Zorgtrajecten in kanker" Zaterdag 27 september 2008 Gasthuisberg, Leuven. Hélène Schoemans, MD KUL, Stem Cell Institute Leuven Cord blood Collection and

More information

Disclosures. I have no disclosures.

Disclosures. I have no disclosures. Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer

More information

MSD HSCT for AA indications, conditioning, GVHD prophylaxis

MSD HSCT for AA indications, conditioning, GVHD prophylaxis MSD HSCT for AA indications, conditioning, GVHD prophylaxis André Tichelli Special thanks to - Jakob Passweg - Régis Peffault de Latour - Gérard Socié The aim for this presentation At the end of this presentation

More information

LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. Anti-thymocyte globulin (horse) for the first-line treatment of aplastic anaemia

LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. Anti-thymocyte globulin (horse) for the first-line treatment of aplastic anaemia LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Anti-thymocyte globulin (horse) for the first-line treatment of aplastic anaemia Review conducted by London and South East Regional Medicines Information December

More information

Conditioning Regimens and Stem Cell Sources for Allogeneic Hematopoietic Cell Transplantation in MDS

Conditioning Regimens and Stem Cell Sources for Allogeneic Hematopoietic Cell Transplantation in MDS Conditioning Regimens and Stem Cell Sources for Allogeneic Hematopoietic Cell Transplantation in MDS H. Joachim Deeg, MD Fred Hutchinson Cancer Research Center and University of Washington/SCCA, Seattle

More information

Hematopoietic Stem Cell Transplantation (HSCT) Overview

Hematopoietic Stem Cell Transplantation (HSCT) Overview Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor, UCSF The Leukemia & Lymphoma Society May 20, 2010

More information

Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012

Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012 Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit Karen Ballen, MD Massachusetts General Hospital June, 2012 OUTLINE Cell Dose HLA Typing HLA C and KIR HLA Antibodies ABO and Racial/Ethnic

More information

Reference: NHS England B04/P/a

Reference: NHS England B04/P/a Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation

More information

11/9/2012. Overview. How Does MDS Develop? MDS: What is it? IPSS to Classify High Risk MDS. How Do We Classify MDS?

11/9/2012. Overview. How Does MDS Develop? MDS: What is it? IPSS to Classify High Risk MDS. How Do We Classify MDS? Overview Treating Patients with Higher Risk Myelodysplastic Syndromes Erica Warlick, MD Assistant Professor of Medicine Division of Hematology, Oncology, and Transplant University of Minnesota November

More information

Cytoreductive Therapy for Autologous Cell Therapy in HIV

Cytoreductive Therapy for Autologous Cell Therapy in HIV Cytoreductive Therapy for Autologous Cell Therapy in HIV Ronald Mitsuyasu, MD Professor of Medicine UCLA Center for Clinical AIDS Research and Education (CARE Center) HSC Transfer from CCR5-delta 32 Donor

More information

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,

More information

STEM CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA

STEM CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA SMALL LYMPHOCYTIC LYMPHOMA Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline

More information

Leading the way in cell & gene therapy

Leading the way in cell & gene therapy Leading the way in cell & gene therapy BIT Small Cap Conference Milan (Italy), November 29, 2016 From genes to therapy Forward-looking statements The presentation contains certain forward-looking statements.

More information

Thinking outside the box :Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation

Thinking outside the box :Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation Thinking outside the box :Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation Arnon Nagler, Sheba Medical Center 1 Introduction 2 THINKING OUTSIDE THE BOX:

More information

Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Company Presentation AGM, 28 June 2016

Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Company Presentation AGM, 28 June 2016 Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders Company Presentation AGM, 28 June 2016 Disclaimer These slides and the accompanying oral presentation

More information

Stem Cell Transplantation

Stem Cell Transplantation Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

Epstein-Barr Virus (EBV) complications following HSCT: from viremia to post transplant lymphoproliferative disease (PTLD) and lymphoma

Epstein-Barr Virus (EBV) complications following HSCT: from viremia to post transplant lymphoproliferative disease (PTLD) and lymphoma Epstein-arr Virus (EV) complications following HSCT: from viremia to post transplant lymphoproliferative p disease (PTLD) and lymphoma Laurie A. Milner, MD Associate Professor, Pediatric Hematology / Oncology

More information

AUTOLOGOUS STEM CELL TRANSPLANTION. Doç. Dr. Alev Akyol Erikci Emsey Hospital Istanbul

AUTOLOGOUS STEM CELL TRANSPLANTION. Doç. Dr. Alev Akyol Erikci Emsey Hospital Istanbul AUTOLOGOUS STEM CELL TRANSPLANTION Doç. Dr. Alev Akyol Erikci Emsey Hospital Istanbul Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells bone

More information

Related haplo identical HSCT Non T depleted. E. Gluckman ESH-EBMT Training course Vienna May 8-10, 2014.

Related haplo identical HSCT Non T depleted. E. Gluckman ESH-EBMT Training course Vienna May 8-10, 2014. Related haplo identical HSCT Non T depleted E. Gluckman ESH-EBMT Training course Vienna May 8-10, 2014. Why do we ask the question? Unrelated cord blood transplant is clinically validated and reproducible

More information

Cord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014

Cord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell

More information

Immune and Targeted Therapies, Including CAR T Cells, for Blood Cancers. Michael B. Maris, MD Director of Research Colorado Blood Cancer Institute

Immune and Targeted Therapies, Including CAR T Cells, for Blood Cancers. Michael B. Maris, MD Director of Research Colorado Blood Cancer Institute Immune and Targeted Therapies, Including CAR T Cells, for Blood Cancers Michael B. Maris, MD Director of Research Colorado Blood Cancer Institute Targeted Therapy Therapy that takes advantage of molecular

More information

Stem Cell Transplantation in Severe Aplastic Anemia

Stem Cell Transplantation in Severe Aplastic Anemia Stem Cell Transplantation in Severe Aplastic Anemia Dr. D. Goodyear MD, FRCPC Division of Hematology and Hematological Malignancies, University of Calgary 1 of 11 Introduction Most cases of aplastic anemia

More information

Introduction. Abstract. Akira Kikuchi, Ryoji Hanada Division of Hematology / Oncology, Saitama Children s Medical Center

Introduction. Abstract. Akira Kikuchi, Ryoji Hanada Division of Hematology / Oncology, Saitama Children s Medical Center Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapse after Initial Allogeneic Transplant in Childhood Leukemia - A Single Center Experience Akira Kikuchi, Ryoji Hanada Division of Hematology

More information

The donor search: the best donor or cord blood unit

The donor search: the best donor or cord blood unit The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation

More information

MDS and Elderly AML. Ryan Mattison, MD University of Wisconsin February 16, 2010

MDS and Elderly AML. Ryan Mattison, MD University of Wisconsin February 16, 2010 MDS and Elderly AML Ryan Mattison, MD University of Wisconsin February 16, 2010 Myelodysplastic Syndrome Incidence/Prevalence WHO Categories International Prognostic Scoring System (IPSS) Treatment and

More information

STEM CELL TRANSPLANTATION FOR NON-HODGKINS LYMPHOMAS

STEM CELL TRANSPLANTATION FOR NON-HODGKINS LYMPHOMAS STEM CELL TRANSPLANTATION FOR NON-HODGKINS LYMPHOMAS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.

More information

Selecting an appropriately matched donor for hematopoietic

Selecting an appropriately matched donor for hematopoietic Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation

More information

Higher Risk MDS. What does high risk mean? 3/21/2011. Question 1: How do we judge the risk and impact of MDS upon you?

Higher Risk MDS. What does high risk mean? 3/21/2011. Question 1: How do we judge the risk and impact of MDS upon you? Treating Higher Risk MDS Arizona, USA Ruben A. Mesa, MD Professor of Medicine Chair, Division of Hematology & Medical Oncology Mayo Clinic Arizona, USA Higher Risk MDS Question 1: How do we judge the risk

More information

Original. Prepared by: Peiman Hematti, M.D. Date: May 16, 2007 Janelle McMannes, R.N., M.S.N.

Original. Prepared by: Peiman Hematti, M.D. Date: May 16, 2007 Janelle McMannes, R.N., M.S.N. Page 1 of 5 Prepared by: Peiman Hematti, M.D. May 16, 2007 Janelle McMannes, R.N., M.S.N. Accepted by: HSCT Program Director Reviewed: Page 2 of 5 I. Purpose: To safely and efficiently administer lymphocytes

More information

What is a Stem Cell Transplantation?

What is a Stem Cell Transplantation? What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am

More information

Experience of FLT3 Inhibitors in Relapsed AML post Allogeneic Haematopoietic Stem Cell Transplantation

Experience of FLT3 Inhibitors in Relapsed AML post Allogeneic Haematopoietic Stem Cell Transplantation Experience of FLT3 Inhibitors in Relapsed AML post Allogeneic Haematopoietic Stem Cell Transplantation Harpreet Kaur 1, Adam Ivey 2, Emma Dasgupta 1, Jennifer Byrne 1, David Grimwade 2, Nigel Russell 1

More information

IL TRAPIANTO DI CELLULE STAMINALI NELLA LEUCEMIA LINFATICA CRONICA: RUOLO DEI FATTORI DI RISCHIO BIOLOGICI

IL TRAPIANTO DI CELLULE STAMINALI NELLA LEUCEMIA LINFATICA CRONICA: RUOLO DEI FATTORI DI RISCHIO BIOLOGICI IL TRAPIANTO DI CELLULE STAMINALI NELLA LEUCEMIA LINFATICA CRONICA: RUOLO DEI FATTORI DI RISCHIO BIOLOGICI Lucia Farina, MD PhD Div. Ematologia e Trapianto di Cellule Staminali Fondazione IRCCS Istituto

More information

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation

More information

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION

More information

Recommendations for CMV and HHV-6 management in patients with hematological diseases Per Ljungman, Rafael de la Camara, Hermann Einsele, Dan

Recommendations for CMV and HHV-6 management in patients with hematological diseases Per Ljungman, Rafael de la Camara, Hermann Einsele, Dan Recommendations for CMV and HHV-6 management in patients with hematological diseases Per Ljungman, Rafael de la Camara, Hermann Einsele, Dan Engelhard, Pierre Reusser, Jan Styczynski, Kate Ward Diagnosis

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 17 February 2000 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER CONCERNING

More information

Disclaimers. For sure everything discussed here is off label. No commercial interest or funding to disclose.

Disclaimers. For sure everything discussed here is off label. No commercial interest or funding to disclose. BMT in SLE. Javier Bolaños Meade, MD Associate Professor of Oncology Marrow and Apheresis Collections Facility Director and Medical Director Graft versus Host Disease Programme Director Sidney Kimmel Comprehensive

More information

OUR JOURNEY THROUGH THE YEARS

OUR JOURNEY THROUGH THE YEARS The King Faisal Specialist Hospital and Research Centre Experience in Hematology, Oncology and Bone Marrow Transplantation OUR JOURNEY THROUGH THE YEARS REGGIE BELKHEDIM A Brief Overview: King Faisal Specialist

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in

More information

The Role of Stem Cell Transplantation in Relapsed / Refractory Aggressive Lymphoma

The Role of Stem Cell Transplantation in Relapsed / Refractory Aggressive Lymphoma The Role of Stem Cell Transplantation in Relapsed / Refractory Aggressive Lymphoma Anna Sureda Haematology Department Institut Català d Oncologia Hospital Duran I Reynals Barcelona, Spain ESH/EBMT Training

More information

The EBMT Cellular Therapy and Immunobiology Symposium

The EBMT Cellular Therapy and Immunobiology Symposium The EBMT Cellular Therapy and Immunobiology Symposium From Transplantation to Gene Therapy: Cellular therapy in evolution November 11 th -13 th, 2015 San Raffaele Scientific Institute Chairman Dr. Chiara

More information

Blood cell development Neutrophil Maturation

Blood cell development Neutrophil Maturation Chronic idiopathic neutropenia (CIN): what we know & don t know Chronic idiopathic neutropenia (CIN): what we know & don t know Background on blood How to diagnosis & theories about its cause Natural history

More information

Graft-versus-host disease (GvHD)

Graft-versus-host disease (GvHD) Graft-versus-host disease (GvHD) This information is an extract from the booklet Understanding donor stem cell (allogeneic) transplants. You may find the full booklet helpful. We can send you a free copy

More information

Allogeneic stem cell transplant in HIV-1-infected individuals

Allogeneic stem cell transplant in HIV-1-infected individuals Allogeneic stem cell transplant in HIV-1-infected individuals Javier Martinez-Picado UNIVERSITAT DE VIC Barriers to cure HIV infection Residual Replication Immune activation Inflammation Latent Infection

More information

Leading the way in cell & gene therapy

Leading the way in cell & gene therapy Leading the way in cell & gene therapy New York, September 2016 From genes to therapy Forward-looking statements The presentation contains certain forward-looking statements. Although the Company believes

More information

Preparing for a Stem Cell Transplant

Preparing for a Stem Cell Transplant Preparing for a Stem Cell Transplant Guest Expert: Stuart, MD Warren Shlomchik, MD www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and Dr. Francine, I am Bruce Barber.

More information

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children s Research Hospital Departments of Hematology, Patient

More information

Epidemiology of SAA according to age of the patients

Epidemiology of SAA according to age of the patients Aplastic anemia in the elderly André Tichelli University of Basel Switzerland Epidemiology of SAA according to age of the patients Incidence of aplastic anemia Overall incidence 2.34 per million inhabitants

More information

Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer

Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_breast_cancer

More information

Frequency of NHL Subtypes in Adults

Frequency of NHL Subtypes in Adults Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults

More information

Setting The setting was secondary care. The economic analysis was conducted in Marseilles, France.

Setting The setting was secondary care. The economic analysis was conducted in Marseilles, France. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle Blaise D,

More information

Infosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?

Infosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation? Infosheet Allogeneic stem cell transplantation in myeloma High-dose therapy and autologous stem cell transplantation is currently the first-line treatment standard of care for younger/fitter myeloma patients.

More information

Graft Failure After HSCT

Graft Failure After HSCT Graft Failure After HSCT Vanderson Rocha, MD, PhD Professor of Haematology- Oxford University Bone Marrow Transplant Unit- Sirio Libanes Hospital- Sao Paulo Scientific Director of Eurocord-Paris Clinical

More information

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use

More information

Not for publication or presentation

Not for publication or presentation MINUTES CIBMTR WORKING COMMITTEE FOR GVHD Orlando, Florida Thursday, February 25, 2010, 2:45 pm 4:45 pm Statisticians: Scientific Directors: Steven Pavletic MD, National Cancer Institute Telephone: 301-402-4899;

More information

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including

More information

Cord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program

Cord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program Cord Blood: that other stem cell source Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program CBMTG April 2012 The problem: In order to perform a BMT from one person to another one needs

More information

MEDICAL COVERAGE POLICY

MEDICAL COVERAGE POLICY Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each

More information

NEW DIRECTIONS IN APLASTIC ANEMIA: WHAT S ON THE HORIZON?

NEW DIRECTIONS IN APLASTIC ANEMIA: WHAT S ON THE HORIZON? NEW DIRECTIONS IN APLASTIC ANEMIA: WHAT S ON THE HORIZON? Amy E. DeZern, MD, MHS Assistant Professor of Oncology and Medicine The Johns Hopkins University School of Medicine Aplastic Anemia is Bone Marrow

More information

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In

More information

HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA

HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA Coverage for services, procedures, medical devices drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage

More information

Cure versus control: Which is the best strategy?

Cure versus control: Which is the best strategy? Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information